中国难治性慢性自发性荨麻疹诊治指南（2025版）

doi:10.35541/cjd.20240674

中华皮肤科杂志 ›› 2025, Vol. 58 ›› Issue (6): 485-496.doi: 10.35541/cjd.20240674

中国难治性慢性自发性荨麻疹诊治指南（2025版）

中华医学会皮肤性病学分会中国医师协会皮肤科医师分会

中华医学会皮肤性病学分会中国医师协会皮肤科医师分会

收稿日期:2024-12-10 修回日期:2025-04-01 发布日期:2025-06-03
通讯作者: 宋志强；高兴华；王刚 E-mail:drsongzq@tmmu.edu.cn; gaobarry@ hotmail.com; xjwgang@fmmu.edu.cn

Guidelines for the diagnosis and treatment of refractory chronic spontaneous urticaria in China （2025 edition）

Chinese Society of Dermatology; China Dermatologist Association

Chinese Society of Dermatology; China Dermatologist Association

Received:2024-12-10 Revised:2025-04-01 Published:2025-06-03
Contact: Song Zhiqiang; Gao Xinghua; Wang Gang E-mail:drsongzq@tmmu.edu.cn; gaobarry@ hotmail.com; xjwgang@fmmu.edu.cn

摘要/Abstract

摘要： 【摘要】难治性慢性自发性荨麻疹（CSU）对H1抗组胺药标准或加倍剂量、或联合使用均抵抗，临床常见，诊疗难度大。现有荨麻疹指南或共识无法满足难治性CSU的高质量规范化管理，有必要制订针对难治性CSU的诊疗指南。中华医学会皮肤性病学分会和中国医师协会皮肤科医师分会组建指南工作组，联合全国29位荨麻疹研究领域专家，全面梳理评估国内外现有循证证据，结合我国国情，经过多轮论证，形成了本指南，旨在为难治性CSU的诊断和治疗提供参考，指导临床实践。

关键词: 慢性荨麻疹, 组胺H1拮抗剂, 诊断, 治疗, 奥马珠单抗, 环孢素, 慢性自发性荨麻疹, 指南

Abstract: 【Abstract】 Refractory chronic spontaneous urticaria （CSU） is clinically common and poses significant diagnostic and therapeutic challenges due to resistance to standard or doubled doses of H1 antihistamines or their combination therapies. Current guidelines or consensus statements on urticaria have not met the needs for high-quality standardized management of refractory CSU, highlighting the necessity for specific guidelines for its diagnosis and treatment. Therefore, a guideline working group was established by the Chinese Society of Dermatology and the China Dermatologist Association, and consisted of 29 leading experts in urticaria research in China. Through a comprehensive review and evaluation of existing Chinese and international evidence-based data, and consideration of the situation in China, this guideline was formulated after multiple rounds of deliberation, aiming to provide guidance on the diagnosis and treatment of refractory CSU and to guide clinical practice.

Key words: Chronic urticaria, Histamine H1 antagonists, Diagnosis, Therapy, Omalizumab, Cyclosporine, Chronic spontaneous urticaria, Guidelines

中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. 中国难治性慢性自发性荨麻疹诊治指南（2025版）[J]. 中华皮肤科杂志, 2025,58(6):485-496. doi:10.35541/cjd.20240674

Qi-Quan CHEN Song Zhi-Qiang WANG Gang. Guidelines for the diagnosis and treatment of refractory chronic spontaneous urticaria in China （2025 edition）[J]. Chinese Journal of Dermatology, 2025, 58(6): 485-496.doi:10.35541/cjd.20240674

参考文献 85

［1］	Kolkhir P, Giménez⁃Arnau AM, Kulthanan K, et al. Urticaria［J］. Nat Rev Dis Primers, 2022,8（1）:61. doi: 10.1038/s41572⁃022⁃00389⁃z.
［2］	Li J, Mao D, Liu S, et al. Epidemiology of urticaria in China: a population⁃based study［J］. Chin Med J （Engl）, 2022,135（11）:1369⁃1375. doi: 10.1097/CM9.0000000000002172.
［3］	Zhang X, Song X, Zhang M, et al. Prevalence and risk factors of chronic urticaria in China: a nationwide cross⁃sectional study［J］. Allergy, 2022,77（7）:2233⁃2236. doi: 10.1111/all.15287.
［4］	中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南（2022版）［J］. 中华皮肤科杂志, 2022,55（12）:1041⁃1049. doi: 10.35541/cjd.20220609.
［5］	Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria［J］. Allergy, 2022,77（3）:734⁃766. doi: 10.1111/all. 15090.
［6］	Curto⁃Barredo L, Archilla LR, Vives GR, et al. Clinical features of chronic spontaneous urticaria that predict disease prognosis and refractoriness to standard treatment［J］. Acta Derm Venereol, 2018,98（7）:641⁃647. doi: 10.2340/00015555⁃2941.
［7］	van den Elzen MT, van Os⁃Medendorp H, van den Brink I, et al. Effectiveness and safety of antihistamines up to fourfold or higher in treatment of chronic spontaneous urticaria［J］. Clin Transl Allergy, 2017,7:4. doi: 10.1186/s13601⁃017⁃0141⁃3.
［8］	Hoskin B, Ortiz B, Paknis B, et al. Exploring the real⁃world profile of refractory and non⁃refractory chronic idiopathic urticaria in the USA: clinical burden and healthcare resource use［J］. Curr Med Res Opin, 2019,35（8）:1387⁃1395. doi: 10.1080/03007995.2019.1586222.
［9］	Maurer M, Costa C, Gimenez Arnau A, et al. Antihistamine⁃resistant chronic spontaneous urticaria remains undertreated: 2⁃year data from the AWARE study［J］. Clin Exp Allergy, 2020,50（10）:1166⁃1175. doi: 10.1111/cea.13716.
［10］	Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations［J］. BMJ, 2004,328（7454）:1490. doi: 10.1136/bmj.328.7454.1490.
［11］	Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations［J］. BMJ, 2008,336（7650）:924⁃926. doi: 10. 1136/bmj.39489.470347.AD.
［12］	Bracken SJ, Abraham S, MacLeod AS. Autoimmune theories of chronic spontaneous urticaria［J］. Front Immunol, 2019,10:627. doi: 10.3389/fimmu.2019.00627.
［13］	He L, Yi W, Huang X, et al. Chronic urticaria: advances in understanding of the disease and clinical management［J］. Clin Rev Allergy Immunol, 2021,61（3）:424⁃448. doi: 10.1007/s12016⁃ 021⁃08886⁃x.
［14］	Zhou B, Li J, Liu R, et al. The role of crosstalk of immune cells in pathogenesis of chronic spontaneous urticaria［J］. Front Immunol, 2022,13:879754. doi: 10.3389/fimmu.2022.879754.
［15］	Church MK, Kolkhir P, Metz M, et al. The role and relevance of mast cells in urticaria［J］. Immunol Rev, 2018,282（1）:232⁃247. doi: 10.1111/imr.12632.
［16］	Peter J, Krause K, Staubach P, et al. Chronic urticaria and recurrent angioedema: clues to the mimics［J］. J Allergy Clin Immunol Pract, 2021,9（6）:2220⁃2228. doi: 10.1016/j.jaip. 2021.03.043.
［17］	Davis M, van der Hilst J. Mimickers of urticaria: urticarial vasculitis and autoinflammatory diseases［J］. J Allergy Clin Immunol Pract, 2018,6（4）:1162⁃1170. doi: 10.1016/j.jaip. 2018.05.006.
［18］	Gusdorf L, Lipsker D. Neutrophilic urticarial dermatosis: an entity bridging monogenic and polygenic autoinflammatory disorders, and beyond［J］. J Eur Acad Dermatol Venereol, 2020,34（4）:685⁃690. doi: 10.1111/jdv.15984.
［19］	中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会. 慢性自发性荨麻疹达标治疗专家共识（2023）［J］. 中华皮肤科杂志, 2023,56（6）:489⁃495. doi: 10.35541/cjd.20230004.
［20］	中华医学会皮肤性病学分会免疫学组. 中国慢性诱导性荨麻疹诊治专家共识（2023）［J］. 中华皮肤科杂志, 2023,56（6）:479⁃488. doi: 10.35541/cjd.20220819.
［21］	于淼, 陈玉迪, 刘擘, 等. 中文版荨麻疹控制评分量表及信效度验证［J］. 中华皮肤科杂志, 2020,53（7）:533⁃538. doi: 10. 35541/cjd.20191190.
［22］	于淼, 陈玉迪, 刘擘, 等. 中文版慢性荨麻疹生活质量问卷（CU⁃Q2oL）信效度验证［J］. 中华皮肤科杂志, 2020,53（12）:992⁃997. doi: 10.35541/cjd.20200091.
［23］	Papapostolou N, Xepapadaki P, Katoulis A, et al. Comorbidities of chronic urticaria: a glimpse into a complex relationship［J］. Front Allergy, 2022,3:1008145. doi: 10.3389/falgy.2022.1008145.
［24］	Kolkhir P, Altrichter S, Asero R, et al. Autoimmune diseases are linked to type Ⅱb autoimmune chronic spontaneous urticaria［J］. Allergy Asthma Immunol Res, 2021,13（4）:545⁃559. doi: 10. 4168/aair.2021.13.4.545.
［25］	Magen E, Mishal J, Zeldin Y, et al. Clinical and laboratory features of antihistamine⁃resistant chronic idiopathic urticaria［J］. Allergy Asthma Proc, 2011,32（6）:460⁃466. doi: 10.2500/aap.2011.32.3483.
［26］	Kovalkova E, Fomina D, Borzova E, et al. Comorbid inducible urticaria is linked to non⁃autoimmune chronic spontaneous urticaria: CURE insights［J］. J Allergy Clin Immunol Pract, 2024,12（2）:482⁃490.e1. doi: 10.1016/j.jaip.2023.11.029.
［27］	Chen Q, Wang W, Yang X, et al. Characteristics and clinical significance of atopy in chronic spontaneous urticaria: a cross⁃sectional observational study［J］. Int Arch Allergy Immunol, 2024,185（12）:1248⁃1253. doi: 10.1159/000540155.
［28］	Chen Q, Yang X, Ni B, et al. Atopy in chronic urticaria: an important yet overlooked issue［J］. Front Immunol, 2024,15:1279976. doi: 10.3389/fimmu.2024.1279976.
［29］	Larenas⁃Linnemann D. Biomarkers of autoimmune chronic spontaneous urticaria［J］. Curr Allergy Asthma Rep, 2023,23（12）:655⁃664. doi: 10.1007/s11882⁃023⁃01117⁃7.
［30］	李邻峰, 王楷. 慢性难治性荨麻疹的诊断及治疗策略［J］. 中华皮肤科杂志, 2017,50（1）:1⁃4. doi: 10.3760/cma.j.issn.0412⁃4030.2017.01.001.
［31］	Bufka J, Sýkora J, Vaňková L, et al. Impact of autoimmune gastritis on chronic urticaria in paediatric patients ⁃ pathophysiological point of views［J］. Eur J Pediatr, 2024,183（2）:515⁃522. doi: 10.1007/s00431⁃023⁃05324⁃2.
［32］	Asero R. Nonsteroidal anti⁃inflammatory drugs hypersensitivity in chronic spontaneous urticaria in the light of its pathogenesis［J］. Eur Ann Allergy Clin Immunol, 2022,54（4）:189⁃191. doi: 10.23822/EurAnnACI.1764⁃1489.227.
［33］	Cornillier H, Giraudeau B, Samimi M, et al. Effect of diet in chronic spontaneous urticaria: a systematic review［J］. Acta Derm Venereol, 2019,99（2）:127⁃132. doi: 10.2340/00015555⁃3015.
［34］	Kolkhir P, Balakirski G, Merk HF, et al. Chronic spontaneous urticaria and internal parasites⁃⁃a systematic review［J］. Allergy, 2016,71（3）:308⁃322. doi: 10.1111/all.12818.
［35］	Watanabe J, Shimamoto J, Kotani K. The effects of antibiotics for helicobacter pylori eradication or dapsone on chronic spontaneous urticaria: a systematic review and meta⁃analysis［J］. Antibiotics （Basel）, 2021,10（2）:156. doi: 10.3390/antibiotics10020156.
［36］	Song Z, Zhai Z, Zhong H, et al. Evaluation of autologous serum skin test and skin prick test reactivity to house dust mite in patients with chronic spontaneous urticaria［J］. PLoS One, 2013,8（5）:e64142. doi: 10.1371/journal.pone.0064142.
［37］	Košec A, Tomljenović D, Ćurković M, et al. Chronic spontaneous urticaria and angioedema in a patient with autoimmune thyroid disease resolved after thyroidectomy［J］. Auris Nasus Larynx, 2022,49（1）:157⁃161. doi: 10.1016/j.anl.2020.08.023.
［38］	Chen Y, Yu M, Huang X, et al. Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both［J］. World Allergy Organ J, 2021,14（1）:100501. doi: 10.1016/j.waojou.2020.100501.
［39］	Yang, Yu R, Qian W, et al. Analysis of the efficacy and recurrence of omalizumab use in the treatment of chronic spontaneous urticaria and chronic inducible urticaria［J］. Int Arch Allergy Immunol, 2023,184（7）:643⁃655. doi: 10.1159/000529250.
［40］	Wang A, Yun Y, Wen Z, et al. Efficacy and safety of omalizumab against chronic spontaneous urticaria: real⁃world study from China［J］. World Allergy Organ J, 2022,15（12）:100719. doi: 10.1016/j.waojou.2022.100719.
［41］	Keskinkaya Z, Kaya Ö, Işık Mermutlu S, et al. Predicting the speed of response to omalizumab in chronic spontaneous urticaria［J］. Int Arch Allergy Immunol, 2024,185（8）:786⁃793. doi: 10.1159/000538291.
［42］	Pierrard G, Bernier C, Du⁃Thanh A, et al. Characterization of omalizumab updosing patterns and predictive factors in chronic spontaneous urticaria: a prospective multicentric observational study［J］. Allergy, 2024,79（9）:2448⁃2457. doi: 10.1111/all.16256.
［43］	Kulthanan K, Chaweekulrat P, Komoltri C, et al. Cyclosporine for chronic spontaneous urticaria: a meta⁃analysis and systematic review［J］. J Allergy Clin Immunol Pract, 2018,6（2）:586⁃599. doi: 10.1016/j.jaip.2017.07.017.
［44］	Kessel A, Toubi E. Cyclosporine⁃A in severe chronic urticaria: the option for long⁃term therapy［J］. Allergy, 2010,65（11）:1478⁃1482. doi: 10.1111/j.1398⁃9995.2010.02419.x.
［45］	Endo T, Toyoshima S, Kanegae K, et al. Identification of biomarkers for predicting the response to cyclosporine A therapy in patients with chronic spontaneous urticaria［J］. Allergol Int, 2019,68（2）:270⁃273. doi: 10.1016/j.alit.2018.09.006.
［46］	Maurer M, Casale TB, Saini SS, et al. Dupilumab in patients with chronic spontaneous urticaria （LIBERTY⁃CSU CUPID）: two randomized, double⁃blind, placebo⁃controlled, phase 3 trials［J］. J Allergy Clin Immunol, 2024,154（1）:184⁃194. doi: 10.1016/j.jaci.2024.01.028.
［47］	Bernstein JA, Maurer M, Saini SS. BTK signaling⁃a crucial link in the pathophysiology of chronic spontaneous urticaria［J］. J Allergy Clin Immunol, 2024,153（5）:1229⁃1240. doi: 10.1016/j.jaci.2023.12.008.
［48］	Metz M, Giménez⁃Arnau A, Hide M, et al. Remibrutinib in chronic spontaneous urticaria［J］. N Engl J Med, 2025, 392（10）:984⁃994. doi: 10.1056/NEJMoa2408792.
［49］	Jain V, Giménez⁃Arnau A, Hayama K, et al. Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks［J］. J Allergy Clin Immunol, 2024,153（2）:479⁃486. doi: 10.1016/j.jaci.2023.10.007.
［50］	Zheng Y, Luo M, Huang J, et al. Evaluating the efficacy and safety of biologic and oral drugs for refractory chronic spontaneous urticaria: systematic review and network meta⁃analysis［J］. J Am Acad Dermatol, 2024,91（6）:1230⁃1233. doi: 10.1016/j.jaad.2024.07.1500.
［51］	Luo XY, Liu Q, Yang H, et al. OSMR gene effect on the pathogenesis of chronic autoimmune urticaria via the JAK/STAT3 pathway［J］. Mol Med, 2018,24（1）:28. doi: 10.1186/s10020⁃018⁃0025⁃6.
［52］	Fukunaga A, Ito M, Nishigori C. Efficacy of oral ruxolitinib in a patient with refractory chronic spontaneous urticaria［J］. Acta Derm Venereol, 2018,98（9）:904⁃905. doi: 10.2340/00015555⁃3006.
［53］	Mansouri P, Mozafari N, Chalangari R, et al. Efficacy of oral tofacitinib in refractory chronic spontaneous urticaria and urticarial vasculitis［J］. Dermatol Ther, 2022,35（12）:e15932. doi: 10.1111/dth.15932.
［54］	Du N, Wang D, Yang J, et al. Case report: exploration of abrocitinib in the treatment of refractory chronic spontaneous urticaria: a case series［J］. Front Immunol, 2024,15:1466058. doi: 10.3389/fimmu.2024.1466058.
［55］	Lu Q, Yang B, Liu L, et al. Efficacy and safety of TLL⁃018 in moderate to severe chronic spontaneous urticaria patients with inadequate response to H1 antihistamine: results from a phase b study ［J］. J Allergy Clin Immun, 2024,153（2）:AB372. doi:10. 1016/j.jaci.2023.11.891.
［56］	Li M, Li Y, Xiang L. Efficacy and safety of tripterygium glycosides as an add⁃on treatment in adults with chronic urticaria: a systematic review and meta⁃analysis［J］. Pharm Biol, 2023,61（1）:324⁃336. doi: 10.1080/13880209.2023.2169468.
［57］	de Silva NL, Damayanthi H, Rajapakse AC, et al. Leukotriene receptor antagonists for chronic urticaria: a systematic review［J］. Allergy Asthma Clin Immunol, 2014,10（1）:24. doi: 10. 1186/1710⁃1492⁃10⁃24.
［58］	Pathania YS, Bishnoi A, Parsad D, et al. Comparing azathioprine with cyclosporine in the treatment of antihistamine refractory chronic spontaneous urticaria: a randomized prospective active⁃controlled non⁃inferiority study［J］. World Allergy Organ J, 2019,12（5）:100033. doi: 10.1016/j.waojou.2019.100033.
［59］	Khan N, Epstein TG, DuBuske I, et al. Effectiveness of hydroxychloroquine and omalizumab in chronic spontaneous urticaria: a real⁃world study［J］. J Allergy Clin Immunol Pract, 2022,10（12）:3300⁃3305. doi: 10.1016/j.jaip.2022.08.051.
［60］	Boonpiyathad T, Sangasapaviliya A. Hydroxychloroquine in the treatment of anti⁃histamine refractory chronic spontaneous urticaria, randomized single⁃blinded placebo⁃controlled trial and an open label comparison study［J］. Eur Ann Allergy Clin Immunol, 2017,49（5）:220⁃224. doi: 10.23822/EurAnnACI.1764⁃1489.11.
［61］	Perez A, Woods A, Grattan CE. Methotrexate: a useful steroid⁃sparing agent in recalcitrant chronic urticaria［J］. Br J Dermatol, 2010,162（1）:191⁃194. doi: 10.1111/j.1365⁃2133.2009.09538.x.
［62］	Unsel M. Safety of Methotrexate in chronic urticaria unresponsive to omalizumab［J］. Iran J Allergy Asthma Immunol, 2021,20（4）:500⁃504.
［63］	Patil AD, Bingewar G, Goldust M. Efficacy of methotrexate as add on therapy to H1 antihistamine in difficult to treat chronic urticaria: a systematic review and meta⁃analysis of randomized clinical trials［J］. Dermatol Ther, 2020,33（6）:e14077. doi: 10. 1111/dth.14077.
［64］	Sandhu J, Kumar A, Gupta SK. The therapeutic role of methotrexate in chronic urticaria: a systematic review［J］. Indian J Dermatol Venereol Leprol, 2022,88（3）:313⁃321. doi: 10. 25259/IJDVL_1145_20.
［65］	Bei W, Qian J, Zilu Q, et al. Comparing four immunosuppressive agents for chronic spontaneous urticaria⁃a network meta⁃analysis［J］. Int Immunopharmacol, 2023,123:110577. doi: 10.1016/j.intimp.2023.110577.
［66］	Dorman SM Jr, Regan SB, Khan DA. Effectiveness and safety of oral tacrolimus in refractory chronic urticaria［J］. J Allergy Clin Immunol Pract, 2019,7（6）:2033⁃2034. doi: 10.1016/j.jaip. 2018. 12.023.
［67］	Kessel A, Bamberger E, Toubi E. Tacrolimus in the treatment of severe chronic idiopathic urticaria: an open⁃label prospective study［J］. J Am Acad Dermatol, 2005,52（1）:145⁃148. doi: 10. 1016/j.jaad.2004.09.023.
［68］	Shahar E, Bergman R, Guttman⁃Yassky E, et al. Treatment of severe chronic idiopathic urticaria with oral mycophenolate mofetil in patients not responding to antihistamines and/or corticosteroids［J］. Int J Dermatol, 2006,45（10）:1224⁃1227. doi: 10.1111/j.1365⁃4632.2006.02655.x.
［69］	Zimmerman AB, Berger EM, Elmariah SB, et al. The use of mycophenolate mofetil for the treatment of autoimmune and chronic idiopathic urticaria: experience in 19 patients［J］. J Am Acad Dermatol, 2012,66（5）:767⁃770. doi: 10.1016/j.jaad.2011. 06.004.
［70］	Raghavendran RR, Humphreys F, Kaur MR. Successful use of mycophenolate mofetil to treat severe chronic urticaria in a patient intolerant to ciclosporin［J］. Clin Exp Dermatol, 2014,39（1）:68⁃69. doi: 10.1111/ced.12156.
［71］	Özkaya E, Babuna Kobaner G, Yılmaz Z, et al. Doxepin in difficult⁃to⁃treat chronic urticaria: a retrospective, cross⁃sectional study from Turkey［J］. Dermatol Ther, 2019,32（4）:e12993. doi: 10.1111/dth.12993.
［72］	Wang J, He L, Yi W, et al. Consecutive injections of low⁃dose interleukin⁃2 improve symptoms and disease control in patients with chronic spontaneous urticaria［J］. Clin Immunol, 2023,247:109247. doi: 10.1016/j.clim.2023.109247.
［73］	Bangsgaard N, Skov L, Zachariae C. Treatment of refractory chronic spontaneous urticaria with adalimumab［J］. Acta Derm Venereol, 2017,97（4）:524⁃525. doi: 10.2340/00015555⁃2573.
［74］	Sand FL, Thomsen SF. TNF⁃alpha inhibitors for chronic urticaria: experience in 20 patients［J］. J Allergy （Cairo）, 2013,2013:130905. doi: 10.1155/2013/130905.
［75］	Sabag DA, Matanes L, Bejar J, et al. Interleukin⁃17 is a potential player and treatment target in severe chronic spontaneous urticaria［J］. Clin Exp Allergy, 2020,50（7）:799⁃804. doi: 10. 1111/cea.13616.
［76］	Bonnekoh H, Kiefer L, Buttgereit T, et al. Anti⁃IL⁃23 treatment with tildrakizumab can be effective in omalizumab⁃refractory chronic spontaneous urticaria: a case series［J］. J Allergy Clin Immunol Pract, 2023,11（8）:2578⁃2580.e1. doi: 10.1016/j.jaip. 2023.05.019.
［77］	Bernstein JA, Singh U, Rao MB, et al. Benralizumab for chronic spontaneous urticaria［J］. N Engl J Med, 2020,383（14）:1389⁃1391. doi: 10.1056/NEJMc2016395.
［78］	Magerl M, Terhorst D, Metz M, et al. Benefit of mepolizumab treatment in a patient with chronic spontaneous urticaria［J］. J Dtsch Dermatol Ges, 2018,16（4）:477⁃478. doi: 10.1111/ddg. 13481.
［79］	Altrichter S, Giménez⁃Arnau AM, Bernstein JA, et al. Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase Ⅱb multinational randomized double⁃blind placebo⁃controlled ARROYO trial［J］. Br J Dermatol, 2024,191（2）:187⁃199. doi: 10.1093/bjd/ljae067.
［80］	Curto⁃Barredo L, Giménez⁃Arnau AM. Treatment of chronic spontaneous urticaria with an inadequate response to H1⁃antihistamine［J］. G Ital Dermatol Venereol, 2019,154（4）:444⁃456. doi: 10.23736/S0392⁃0488.19.06274⁃6.
［81］	Combalia A, Losno RA, Prieto⁃González S, et al. Rituximab in refractory chronic spontaneous urticaria: an encouraging therapeutic approach［J］. Skin Pharmacol Physiol, 2018,31（4）:184⁃187. doi: 10.1159/000487402.
［82］	Mitzel⁃Kaoukhov H, Staubach P, Müller⁃Brenne T. Effect of high⁃dose intravenous immunoglobulin treatment in therapy⁃resistant chronic spontaneous urticaria［J］. Ann Allergy Asthma Immunol, 2010,104（3）:253⁃258. doi: 10.1016/j.anai.2009.12.007.
［83］	Chen J, Zeng X, Chen Q, et al. Efficacy of NB⁃UVB as add⁃on therapy to antihistamine in the treatment of chronic urticaria: a systematic review and meta⁃analysis［J］. Dermatol Ther （Heidelb）, 2021,11（3）:681⁃694. doi: 10.1007/s13555⁃021⁃00510⁃2.
［84］	Chen Q, Luo J, Yang X, et al. Biomarkers of autologous whole blood injection efficacy in patients with chronic spontaneous urticaria with autoreactivity: a preliminary study［J］. Int Arch Allergy Immunol, 2024,185（2）:190⁃195. doi: 10.1159/000534662.
［85］	Zheng H, Xiao XJ, Shi YZ, et al. Efficacy of acupuncture for chronic spontaneous urticaria: a randomized controlled trial［J］. Ann Intern Med, 2023,176（12）:1617⁃1624. doi: 10.7326/M23⁃1043.

[1]	李恩泽陈璐张楚翘姚昱旭焦晴晴季江. 肠道菌群及短链脂肪酸与慢性自发性荨麻疹相关性研究进展[J]. 中华皮肤科杂志, 2025, 58(6): 577-581.
[2]	唐汇洋杨芷样希姚正秋陈邦涛郝飞. 氧化三甲胺参与慢性自发性荨麻疹发病的机制研究[J]. 中华皮肤科杂志, 2025, 58(6): 515-522.
[3]	黄雪薇陈奇权杨显杰陈安祺王欢邓思思翟志芳王娟宋志强. 荨麻疹性血管炎与伴色素沉着慢性自发性荨麻疹的临床与病理特征对比分析[J]. 中华皮肤科杂志, 2025, 58(6): 508-514.
[4]	肖萌赵美茹张新美张俊艳亓玉青王惠平. 慢性自发性荨麻疹患者疾病负担的单中心回顾性分析[J]. 中华皮肤科杂志, 2025, 58(6): 530-535.
[5]	梁碧华陈紫嫣李华平邹荟林天一李晓峰张珞喻李圣信欧珊珊陈教全李润祥朱慧兰. Olink靶向蛋白质组学技术分析慢性自发性荨麻疹患者抗组胺药治疗抵抗相关血清炎症因子[J]. 中华皮肤科杂志, 2025, 58(6): 523-529.
[6]	赵美茹肖萌张新美张俊艳亓玉青王惠平. 奥马珠单抗治疗妊娠期或哺乳期慢性自发性荨麻疹患者8例临床分析[J]. 中华皮肤科杂志, 2025, 58(6): 536-539.
[7]	邱里肖汀. 布鲁顿酪氨酸激酶抑制剂在慢性自发性荨麻疹治疗中的进展[J]. 中华皮肤科杂志, 2025, 58(6): 563-567.
[8]	梁高澎杨显杰陈奇权宋志强. 慢性荨麻疹共病的研究现状及进展[J]. 中华皮肤科杂志, 2025, 58(6): 567-572.
[9]	宋志强杨显杰陈奇权. 慢性自发性荨麻疹的疾病管理和疾病修饰：新时代下的需求与展望[J]. 中华皮肤科杂志, 2025, 58(6): 503-507.
[10]	于金蕾吴桥芳孙悦鑫包军周映. 佩索利单抗治疗6例泛发性脓疱型银屑病临床观察[J]. 中华皮肤科杂志, 2025, 0(5): 20240440-e20240440.
[11]	黄和金李馨雅席文文肖霞蒋斌杨锋. 微创旋切术治疗腋臭患者3 000例术后并发症回顾分析[J]. 中华皮肤科杂志, 2025, 0(5): 20230291-e0230291.
[12]	中国儿童鲜红斑痣诊断和治疗专家共识制订专家组中国医师协会皮肤科医师分会儿童学组. [开放获取] 儿童鲜红斑痣诊疗专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(5): 396-404.
[13]	中国医师协会皮肤科医师分会中华医学会皮肤病学分会治疗学组中国医疗保健国际交流促进会皮肤医学分会国家皮肤与免疫疾病临床医学研究中心中国罕见病联盟皮肤罕见病专业委员会. 大疱性类天疱疮诊疗专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(5): 405-415.
[14]	中国中西医结合学会皮肤性病专业委员会皮肤肿瘤学组中国抗癌协会黑色素瘤专业委员会中国抗癌协会皮肤肿瘤整合康复专业委员会. [开放获取] 色素痣诊疗专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(5): 387-395.
[15]	白璐楚妍刘园园朱才勇. 慢性手部湿疹的治疗进展[J]. 中华皮肤科杂志, 2025, 58(5): 477-480.

中国难治性慢性自发性荨麻疹诊治指南（2025版）

Guidelines for the diagnosis and treatment of refractory chronic spontaneous urticaria in China （2025 edition）

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 85

相关文章 15

Metrics

本文评价

推荐阅读 10